Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3358-x
Abstract: PurposeThe aim of this study is to evaluate the relationship between the CYP450 enzyme family and cisplatin toxicity.MethodsThis article examined a collection of studies suggesting that CYP450 enzymes may influence cisplatin toxicity. We performed a… read more here.
Keywords: involvement cytochrome; cisplatin; toxicity; cisplatin toxicity ... See more keywords
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacological Research"
DOI: 10.1016/j.phrs.2017.03.004
Abstract: Graphical abstract Figure. No Caption available. ABSTRACT Chronic myeloid leukemia (CML) is characterized by the expression of the oncoprotein, BCR‐ABL. BCR‐ABL inhibitors revolutionized CML chemotherapy while blast crisis (BC) CML patients are less responsive. Since… read more here.
Keywords: cml cells; p53; cml; cisplatin toxicity ... See more keywords
Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells
Sign Up to like & getrecommendations! Published in 2017 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000467
Abstract: Cancer cells may acquire drug resistance by activating DNA repair signaling. Poly ADP-ribose polymerase (PARP) plays an important role in DNA repair and it is overexpressed in many cancers including chronic myeloid leukemia (CML). PARP… read more here.
Keywords: poly adp; toxicity; ribose polymerase; chronic myeloid ... See more keywords